Display Settings:

Format

Send to:

Choose Destination
    Leuk Res. 2010 Feb;34(2):173-6. Epub 2009 Aug 12.

    Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia.

    Source

    Hematology, Quest Diagnostics Nichols Institute, Building A, Hematopathology/Oncology R&D, 33608 Ortega Highway, San Juan Capistrano, CA 92675, United States. jeanmarie.x.bruey@questdiagnostics.com

    Abstract

    Tissue-based determination of Ki-67, a marker of cellular proliferation, has shown prognostic value in solid tumors and hematological malignancies. We developed and validated an electrochemiluminescence-based method for sensitive measurement of circulating Ki-67 in plasma (cKi-67). This assay demonstrated significantly higher levels of cKi-67 in patients with newly diagnosed acute lymphoblastic leukemia (ALL) (n=27; median, 762; range, 0-4574U/100 microL) than in healthy control subjects (n=114; median, 399; range, 36-2830U/100 microL). Moreover, elevated plasma cKi-67 was associated with significantly shorter survival in ALL patients (P=0.05). These findings suggest that Ki-67 can be detected in circulation and has potential for use as a biomarker for predicting clinical behavior in ALL.

    Copyright 2009 Elsevier Ltd. All rights reserved.

    PMID:
    19679351
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk